AtriCure projects 2026 adjusted EBITDA of $91M-$94M as it targets BoxX-NoAF enrollment completion by year-end
What it means
- What to watch: In healthcare, the calendar is the catalyst: trial readouts, FDA dates and pricing rules drive most of the moves.
- How the stock is trading: $ATRC +0.89% in the latest session.
- Timing: It arrived overnight — the change beside it belongs to a session that had already packed up and gone home. Market holidays are not detected.
Where the stock stands
$ATRC last traded at $60.41, +0.89% on the session. That puts it 4.1% shy of its 52-week high of $63.00 and 138% clear of its low of $25.36 — within a tenth of its 52-week high. Over the year it has ranged 148% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $ATRC page.
How much coverage it is getting
Nothing else on $ATRC in the last 30 days: this is the only story Wook has filed, so there is no run to measure it against yet. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$ATRC earnings today. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the hard numbers get the last word soon.
What to watch next
For the receipts, the $ATRC page has the full chart, the filings and the valuation model these figures come from. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. And Wook AI, up top, will happily do the math — how far $ATRC sits from its high, or how this week's coverage stacks up.
How this analysis was made
Seeking Alpha published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $ATRC. It carried $91 million and $94 million, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.